You may find more results for this query on our sister sites: GenomeWeb and 360Dx.
The startup has exclusively licensed an integration engine from the University of Miami to augment its VIPER platform and improve trial recruitment specifically in precision oncology.
GNS Healthcare will apply its AI and simulation technology to data from the CoMMpass study in search of insights on disease progression and drug response.
The tool, which has been validated in two independent patient cohorts, uses artificial intelligence to predict patients likely to benefit from upfront FOLFOX.
Through the Onco AI-Med collaboration, 30 partner institutions from 11 counties have access to IndivuMed's multiomics database and high-quality tissue sample repository.
With the help of a companion diagnostic, the firm plans to file a new drug application with the FDA for the previously abandoned TKI in the second half of 2020.
Transgene and NEC are working together to use artificial intelligence to tailor immunotherapy to individual patients.
Researchers developed a feature mapping algorithm to pair cancer patients with precision oncology trials at Stanford but say increased clinical trial standardization is needed.
The companies aim to develop technologies for interpreting cancer genome data, with a focus on linking genetic profiles with treatment responses.
The results are of interest to drugmakers looking for scalable technology solutions for assessment of PD-L1 for predicting immunotherapy response.
Microsoft is applying its Project Hanover AI to Jackson Laboratory's Clinical Knowledgebase to help tumor boards find appropriate therapies based on tumor mutations.